Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

VLA15

Vaccine (Recombinant protein vaccine) · Immune activation, directed at Borrelia burgdorferi outer surface protein A (OspA) · developed by Pfizer

Phase 3 Most advanced trial (none active)

2 Registered trials

What is VLA15?

VLA15 is a multivalent vaccine candidate based on outer surface protein A (OspA) of Borrelia bacteria, the agents of Lyme disease. It is given by intramuscular injection in the deltoid muscle on a three-dose schedule, and it is studied for the prevention of Lyme borreliosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Vaccine (Recombinant protein vaccine)
Targets: Borrelia burgdorferi outer surface protein A (OspA) (antigen)
Mechanism: Immune activation, directed at Borrelia burgdorferi outer surface protein A (OspA)
Therapy area: Infectious disease
Developer: Pfizer
In trials of: VALN
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05477524	Phase 3	Lyme Disease	Completed	VALN
NCT03010228	Phase 1	Lyme Borreliosis, Nervous System	Completed	VALN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Lyme Borreliosis, Nervous SystemLyme Disease

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z